Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Cellular senescence
Research brief

Review separates two meanings of "telomeric autophagy"

This review argues that "telomeric autophagy" has described two non-equivalent processes: autophagy triggered by damaged telomeres, which is established, and selective degradation of telomeric chromatin, for which the authors found no direct evidence. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The review states that "telomeric autophagy" has been used for two processes that are not equivalent, and that much confusion follows from conflating them. [1]

  2. Autophagy induced by dysfunctional telomeres is described as established, with telomeric damage during replicative crisis activating cGAS-STING signalling and the autophagy machinery. [1]

  3. For selective autophagic degradation of telomeric chromatin, the authors found no direct evidence, and cancer was the only setting where telomeric and autophagic endpoints were measured in the same system. [1]

The source at a glance

Study type / format
Review (abstract only)
Population / context
Cells and disease literature discussed in a review of telomeres, autophagy, aging and disease
Summary based on
Study abstract
Original publication
September 29, 2026

Two processes conflated under one term

Telomeres are repetitive DNA sequences that cap chromosome ends and protect genomic stability. The review states that the term "telomeric autophagy" has been used for two processes that are not equivalent, and that much confusion in this literature follows from conflating them. The authors therefore separate the two throughout their review.

Supporting source [1]

Autophagy induced by dysfunctional telomeres is established

The first process is the induction of autophagy by dysfunctional telomeres, which the review calls established. During replicative crisis, telomeric damage generates cytosolic chromatin fragments that activate cGAS-STING signalling and engage the autophagy machinery. This induction is described as specific to telomeric damage and not produced by intrachromosomal breaks, and it has been independently reproduced in cells maintaining telomeres through alternative lengthening.

Supporting source [1]

No direct evidence for degrading telomeric chromatin

The second process is the selective autophagic degradation of telomeric chromatin itself. For this the authors were unable to identify direct evidence: no receptor bridging telomeric chromatin to ATG8-family proteins has been described, telomeric cargo has not been recovered from autolysosomes, and no compound acts selectively on the process. The review grades the evidence for each claim and applies the same grading to the disease literature, where cancer emerges as the only setting in which telomeric and autophagic endpoints have been measured in the same system.

Supporting source [1]

How to interpret this

This is an abstract; the full text was not reviewed. The abstract reports no study design, sample, follow-up or numerical results, and its statements about evidence are the authors' review conclusions.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
Telomeric autophagy in human health, aging, and diseases.

Li X, Wu X. · europepmc.org · September 29, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    two processes that are not equivalent
  2. Finding 2 ↑

    The first is the induction of autophagy
  3. Finding 3 ↑

    we were unable to identify direct evidence

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…